Related references
Note: Only part of the references are listed.Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial
Francesco Perrone et al.
EUROPEAN JOURNAL OF CANCER (2019)
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
Sabino De Placido et al.
LANCET ONCOLOGY (2018)
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
P. A. Francis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial
Ian Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Hongchao Pan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials
Meredith M. Regan et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy
Meritxell Bellet et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data The PRISMA-IPD Statement
Lesley A. Stewart et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
R. Coleman et al.
LANCET (2015)
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials
Juerg Bernhard et al.
LANCET ONCOLOGY (2015)
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
M. Gnant et al.
ANNALS OF ONCOLOGY (2015)
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
Olivia Pagani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27-A Randomized Controlled Phase III Trial
Paul E. Goss et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04)
Hiroyuki Takei et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
K. Albain et al.
LANCET (2012)
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial
Norikazu Masuda et al.
LANCET ONCOLOGY (2012)
Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care
R. Peto
BRITISH JOURNAL OF CANCER (2011)
Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial
Georg Pfeiler et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Michael Gnant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Share Paper
